The very impressive Zika and hemorrhagic fever results in animals are new talking points. Also, because major issues have arisen for Sanofi's Dengvaxia, the opportunities in the flavivirus area, given that GOVX anticipated and designed its Zika virus vaccine to avoid the problem (antibody dependent enhancement), may be opening up. This may interest a suitor.